An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

Trial Profile

An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Mocetinostat (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 22 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 17 Feb 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 02 Jun 2015 Current trial status presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top